MapLight Therapeutics is recruiting patients for IRIS, a Phase 2 clinical trial evaluating ML-004, the company’s lead clinical compound for patients with Autism Spectrum Disorder. The study will assess whether there is an impact of ML-004 treatment on the core social communication deficits and on the associated features of irritability in ASD.
The randomized, double blind, placebo-controlled study will evaluate the efficacy and safety profile of ML-004 in up to 150 adults and adolescents with ASD. The study will be conducted in the United States, Australia, and Canada, and is fully funded by MapLight.
All Clinical Trials
Information about current and past clinical trials sponsored by MapLight is available on the official ClinicalTrials.gov website maintained by the US National Library of Medicine. When available, results and links to publications of clinical trial data will be made available on this site.